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A 32-yr-old woman was admitted to New England
Medical Center Hospital (NEMCH) for the first time
for evaluation and management of renal failure.
The patient was first noted to have persistent pro-
teinuria at age nine. She was well until age 18 when
she rapidly gained weight (11.4 kg) and developed
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marked edema. An i.v. urogram was normal, and she
was treated with bed rest, salt restriction, and diuret-
ics. During the next several years, she had several
transient episodes of edema and weight increase.
At age 21 during her first pregnancy, she was
hospitalized for evaluation of progressive dyspnea,
edema, and headaches. Examination disclosed a
blood pressure of 160/90 mm Hg and minimal periph-
eral edema. Laboratory findings were: hemoglobin,
10.1 g; blood urea nitrogen (BUN), 13 mg; serum
creatinine, 1.2 mg; and serum albumin, 3.7 g/100 ml.
Results of urinalysis revealed proteinuria (2+) and
an occasional white blood cell. The blood pressure
was controlled, and the pregnancy was uneventful.
At age 28, laboratory findings disclosed the follow-
ing: BUN, 52 mg; serum albumin, 2.5 g; serum cal-
cium, 9.7 mg; and serum phosphorus, 3 mg/100 ml.
One year later, hypercalcemia was first noted when
the serum concentrations for calcium and phospho-
rus were 12.3 and 3.4 mg/lO0 ml, respectively: the
BUN was 49 mg/100 ml.
Nine months later, the patient developed nausea
and vomiting and was hospitalized. Laboratory find-
ings at that time were: BUN, SO mg; serum calcium,
13.5 mg; serum phosphorus, 4.4 mg; serum uric acid,
11.5 mg; and serum albumin, 3.3 g!l00 ml. Results of
urinalysis revealed proteinuria (4+). The patient was
treated with i.v. fluids, prednisone, allopurinol, and
mithramycin and subsequently discharged. One
month later, laboratory findings were: BUN, 63 mg;
serum creatinine, 3.1 mg; serum uric acid, 9.7 mg:
serum calcium, 13.3 mg; serum phosphorus, 4.6 mg;
and serum albumin, 3.1 g/100 ml. Despite treatment
with prednisone, diuretics, and allopurinol, the pa-
tient developed recurrent episodes of nausea, vomit-
ing, diarrhea, bone pain, arthralgias, and muscle
weakness.
Six months later, laboratory findings disclosed the
following: serum calcium, 15.4 mg: serum phospho-
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rus, 6.8 mg; serum albumin, 2.8 g; BUN, 68 mg; and
serum creatinine, 4.8 mgIlOO ml. An abdominal plain
film was allegedly normal, and a bone survey was
normal except for the skull, which showed "salt and
pepper" porosity. A subtotal parathyroidectomy
was performed; three large glands and part of the
fourth gland were removed. The histological diagno-
sis was chief cell hyperplasia; no adenoma was
found. Postoperatively, the serum creatinine level
fell to 3.5 mg, and the serum calcium fell to 7.2 mgI
100 ml. The serum phosphorus concentration was 6.1
mgIlOO ml, and the alkaline phosphatase was 2.6
Bodansky U. The patient was discharged on a regi-
men of vitamin D (100,000 U/day), calcium lactate,
ethacrynic acid, and methyldopa.
Nine months later while receiving the same medi-
cations, the serum calcium concentration was 8 mg;
the serum phosphorus was 6.8 mg; and the BUN was
85 mg/100 ml. Seven months later, the serum calcium
concentration was 9.1 mg; the serum phosphorus
was 7.6 mg; and the BUN was 85 mg/ 100 ml.
Eight months later (1 month prior to admission to
NEMCH), the patient developed anorexia, pruritus,
and progressive fatigue. Because of emotional stress
and depression, she omitted her medications and,
shortly thereafter, was admitted to a hospital. On
admission, physical examination revealed a blood
pressure of 220/140 mm Hg and a Grade II hyperten-
sive retinopathy. Laboratory findings at that time
were: serum calcium, 8 mg: serum phosphorus, 12
mg; BUN, 164 mg; and serum creatinine, 12.5 mg/
100 ml. Results of urinalysis revealed: proteinuria
(4+); 15 to 20 red blood cells; and 0 to 2 white blood
cells/high power field. She was treated with methyl-
dopa and i.v. fluids and transferred to NEMCH.
On admission, the patient was somnolent. Physical
examination disclosed the following findings: blood
pressure, 150/100 mm Hg; pulse, 80 and regular;
respirations, 22/mm; temperature, 36° C; no band
keratopathy; arteriolar narrowing and arteriovenous
nicking in the optic fundi; diffuse bone tenderness,
most markedly over the ribs; no costovertebral angle
tenderness; and no presacral or peripheral edema.
Cardiac examination revealed a Grade il/VI systolic
ejection murmur at the lower left sternal border and
apex. Laboratory findings revealed the following:
hemoglobin, 9.5 g/100 ml; white blood cell count,
7,400/mm3; platelet count, 312,000/mm3; serum so-
dium, 133 mEq; serum potassium, 3.4 mEq; serum
chloride, 95 mEq; total carbon dioxide, 19 mEq/liter;
BUN, 147 mg; serum creatinine, 9.7 mg; serum cal-
cium, 9.2 mg; serum phosphorus, 12 mg; total serum
protein, 5.6 g; and serum albumin, 3.1 g/100 ml.
Results of urinalysis revealed: pH, 6: proteinuria
(3+): 4 to 5 red blood cells: 5 to 7 white blood cells:
and several coarse granular casts; the urine culture
was sterile. A chest X-ray film was normal. Abdomi-
nal plain film (Fig. 1) revealed the following: kidneys
with normal contours; right kidney, 13.2 cm in
length; left kidney, 12.2 cm in length; a diffuse in-
crease in density of both kidneys with focal areas
calcification consistent with nephrocalcinosis; and a
slight increase in the bone density of the pelvis,
lower ribs, and spine. Initially, the patient was
treated with oral phosphate binders, antihyperten-
sive medications, diuretics, and a low-protein diet.
Progressive impairment of renal function ensued,
and two months later hemodialysis was begun.
Discussion
In summary, a 32-yr-old woman with a history of
proteinuria since age nine developed edema and a
picture that sounds like nephrotic syndrome at age
18. At that time, an i.v. urogram was said to be
nonnal. Episodes of edema punctuated the rest of
her clinical course.
During the patienf s first pregnancy at age 21, she
developed hypertension for the first time. Proteinuria
was again present, and her serum albumin concentra-
tion was normal. Her blood urea nitrogen (BUN)
concentration was 13 mg, and her serum creatinine
concentration was 1.2 mg/100 ml. Since her serum
creatinine concentration might well have been ex-
pected to be in the range of 0.5 0.6 mg/lOO ml as a
result of the physiologic hyperperfusion of the kid-
neys during pregnancy, it is reasonable to assume
that the serum creatinine concentration of 1.2 mg/100
ml represents early evidence of renal dysfunction
[1].
There is no further information to evaluate this
possibility and, in fact, no further information at all
until laboratory findings at age 28 disclosed a BUN
concentration of 52 mg, a serum albumin of 2.5 g, a
serum calcium of 9.7 mg, and a serum phosphorus of
3 mg/l00 ml. Recognizing that approximately half of
the serum calcium is bound to protein, and the ma-
jority of that to albumin, we can correct the calcium
for the low albumin concentration (assuming that for
each 1 g/100 ml decrement in the concen tration of
albumin, the total serum calcium concentration
would be reduced by 0.8 to 1.0 mg/100 ml). With this
correction, her total serum calcium concentration
can be estimated to be in the 10.5 to 10.7 mg/100 ml
range. Thus, she may very well have had an elevated
serum ionized calcium concentration at age 28. One
year later, her BUN concentration was 49 mg/100 ml.
She had unequivocal hypercalcemia with a serum
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Fig. 1. Abdominal plain film showing bilateral nephrocalcinosis. Calcification is both diffuse
and spotty in nature.
calcium concentration of 12.3 mg and a serum pho-
phorus concentration of 3.4 mg/100 ml.
Nine months later, her serum calcium concentra-
tion was up to 13.5 mg, and her serum phosphorus
was up to 4.4 mg/100 ml. Her serum concentration of
albumin was 3.3 g, and her BUN was 50mg! 100 ml.
Treatment at that time with prednisone, allopurinol,
and mithramycin could not have been expected to
produce any permanent reduction in the serum cal-
cium concentration; in point of fact, one month later
the BUN was 63 mg/100 ml, and the patient's hyper-
calcemia was unchanged. Diuretics were added to
her therapy.
Six months later, her serum calcium concentration
reached its peak at 15.4 mg/l00 ml, and hyperphos-
phatemia was present for the first time. She also had
a serum creatinine concentration of 4.8 mg/100 ml.
X-ray films of her abdomen and bones were said to
be normal, but films of her skull were consistent with
hyperparathyroidism. Surgical removal of three
parathyroid glands and a portion of the fourth gland
was performed. Pathologic examination revealed
chief cell hyperplasia; no adenoma was found. Her
serum calcium concentration fell into the normal
range and was never again elevated. Her serum cre-
atinine level fell transiently, but then began to rise
again, and she was treated with vitamin D, calcium
lactate, ethacrynic acid, and alpha methyldopa.
Over the next 1.5 years, the patient remained hy-
perphosphatemic and became clinically uremic. She
was transferred to this institution with severe hyper-
phosphatemia (12 mg!100 ml) and a serum creatinine
concentration of 12.5 mg/100 ml. At that time, the
patient showed evidence of nephrocalcinosis on ab-
dominal films (Fig. 1) and was admitted for manage-
ment of her chronic renal failure.
This patient appears to have chronic renal disease,
most likely chronic glomerulonephritis complicated
by hypercalcemia. It would not be profitable to sec-
ond guess her management when she was 18 since
we do not have enough information about her under-
lying renal disease or the reasoning behind her treat-
ment. It is worth noting that she may have had
nephrotic syndrome at that time. More than a decade
later, we still await the results of good controlled
studies to define more accurately the best modes of
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There do seem to be a few key questions relative
to this patient's course that I think we should try to
answer. First, and most important, was this patient's
hypercalcemia a complication of her underlying renal
disease, or was it a second primary disorder? In
either case, the presence of the hypercalcemia un-
questionably complicated her renal disease and prob-
ably accelerated the deterioration in renal function.
Second, what should have been done about her
hypercalcemia?
To belabor the differential diagnoses when the
diagnosis is obvious seems gratuitous. Therefore, I
will state unequivocally that this patient had autono-
mous hyperparathyroidism. The question is whether
it was primary or tertiary. I will take the position that
her hypercalcemia was the result of primary hyper-
parathyroidism. I will explain why I believe this to be
the case, and then I will attack my own premise,
before you can, to see if other reconstructions of the
events are tenable.
That this patient had hyperparathyroidism seems
unquestionable. She had hypercalcemia associated
with a normal or slightly low serum phosphorus
concentration; she had hyperplasia of her parathy-
roid glands, and her serum calcium concentration
returned to normal after a subtotal parathyroidec-
tomy. If measures had been made of her immuno-
reactive parathyroid hormone or of nephrogenous
cyclic AMP [2], which is a more sensitive measure of
parathyroid function, they would undoubtedly have
been elevated early in the course of her illness. If she
had had a single, clear-cell adenoma, my argument
would be simple; the pathologic examination of her
parathyroid glands, however, showed chief cell hy-
perplasia, which is more typical of secondary hyper-
parathyroidism and some cases of autonomous ter-
tiary hyperparathyroidism. Chief cell hyperplasia
may be found in patients with the multiple endocrine
adenoma syndrome, and it has become clear in re-
cent years that chief cell hyperplasia may be found in
as many as 10% or more of patients with primary
hyperparathyroidism [3]. Nonetheless, such hyper-
plasia is found most commonly in secondary hyper-
parathyroidism, and therefore it is important to ex-
amine the patient's course for evidence of stimuli
that would have produced secondary parathyroid
hyperplasia.
Pathologically, there are said to be changes char-
acteristic of a stimulated hyperplastic parathyroid
gland, which include vacuolation of chief cells and an
increased number of transitional oxyphil cells [31.
There is nothing in the record to indicate whether
these histological changes were found in this pa-
tient's glands, but it would be worth reviewing the
pathology to assess this possibility. Whether it is
possible to distinguish between secondary hyperpla-
sia stimulated by hypocalcemia and primary chief
cell h yperplasia on the basis of these pathologic find-
ings is questionable. I certainly would not be com-
fortable assessing primary versus secondary hyper-
parathyroidism on the basis of histology alone. In a
recent study of cell suspensions obtained from hu-
man parathyroid glands, a different response was
observed in cells from primary hyperplastic versus
adenomatous glands [4]. It was claimed that release
of parathyroid hormone is more easily suppressed in
hyperplastic tissue than in adenomatous tissue as the
calcium concentration in the incubation medium is
raised. Though differences in the performance of
these parathyroid cells in vitro are statistically signif-
icant, the differences are small. Furthermore, both
hyperplastic and adenomatous gland cells may ex-
hibit suppressibility or lack of suppressibility. Thus,
this approach in vitro is physiological, but does not
yield a separation clean enough to help us answer our
question. In all fairness, the approach has not been
applied to the question of secondary versus primary
or tertiary hyperparathyroidism.
Physiologically, parathyroid gland hyperplasia and
parathyroid hormone synthesis are stimulated by a
reduction in the concentration of serum ionized cal-
cium. In renal insufficiency, as the glomerular filtra-
tion rate (GFR) falls, there is a transient retention of
phosphorus if the phosphorus intake is unchanged.
The retained phosphorus has at least two important
effects: first, it directly lowers serum ionized cal-
cium; and, second, it inhibits the production of 1,25—
dihydroxy vitamin D by the proximal renal tubular
cell. This metabolite of vitamin D plays an important
role in stimulating intestinal absorption of calcium,
and a reduction in its activity leads to a reduced
calcium absorption. Thus, for at least two reasons an
increased serum phosphorus concentration lowers
the concentration of serum ionized calcium and stim-
ulates the synthesis of parathyroid hormone. The
stimulation of parathyroid hormone synthesis re-
duces phosphorus reabsorption in the proximal tu-
bule of the kidney and enhances calcium reabsorp-
tion in the distal tubule. These effects result in a
lowering of serum phosphorus concentration, a rise
in serum calcium concentration, a return of the pro-
duction of 1 ,25—dihydroxy vitamin D toward normal,
and a new steady state at which the serum parathy-
roid hormone level is slightly elevated. With further
reduction in GFR, this series of events is repro-
duced, and the parathyroid hormone level rises pro-
gressively [5]. This process seems capable of main-
taining the serum phosphorus concentration within
the normal range until the GFR falls below 25% of
normal. For reasons that are not clear, at glomerular
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filtration rates below this level, further reductions in
tubular reabsorption of phosphate are not propor-
tional to the reduction in filtration rate, and the
serum phosphorus concentration rises. In any event,
nothing in this simple scheme can account for serum
calcium concentrations rising above normal. In fact,
whenever the serum calcium concentration reaches a
high normal range, parathyroid hormone production
is suppressed, and a new steady state is achieved.
The parathyroid glands in such patients show chief
cell hyperplasia and the evidence of stimulation indi-
cated earlier. For the glands to become autonomous,
as has been reported in some patients with prolonged
hypocalcemia, either from intestinal malabsorption
or renal failure, it is necessary to postulate a pro-
longed period of stimulation without appropriate
feedback inhibition. That is, there must be evidence
of prolonged phosphate retention, or prolonged re-
ductions in serum ionized calcium concentration, or
both. Such prolonged and continuous stimulation of
the parathyroid glands may result in autonomous
function. In the patient under discussion, there is no
evidence for hypocalcemia at all, and certainly none
for a prolonged period of hypocalcemia. Nor is there
any evidence of even a high normal serum phospho-
rus concentration, let alone an elevated concentra-
tion, prior to the development of hypercalcemia.
Therefore, there is no evidence of ongoing stimula-
tion of the parathyroid glands. A comparison of this
patient's blood chemistries with those of 195 patients
with renal failure reported in a series several years
ago highlights the fact that patients who develop
renal failure over prolonged periods of time rarely
develop hypercalcemia prior to dialysis or transplan-
tation [6]. Only one of the 195 patients developed
clinically important hypercalcemia prior to dialysis
or transplantation. Seven patients in the series had
occasional elevations of their serum calcium concen-
tration, but their mean calcium concentrations were
not elevated. Similarly, only one of the 195 patients
had a serum phosphorus concentration below nor-
mal. Thus, our patient had neither a stimulus for the
development of hypercalcemia, nor a pattern of
chemical abnormality of serum calcium and phos-
phorus consistent with the usual patient with renal
failure.
What other events might have led to parathyroid
stimulation early in her renal failure? In a recent
study by Bordier et al, the evidence suggests that
administration of 1,25—dihydroxy vitamin D or 25—
hydroxy vitamin D to patients with renal osteodys-
trophy can effect an increase in serum calcium con-
centrations and a lowering of parathyroid hormone
levels [7]. These data are consistent with previous
evidence which indicated that 1,25—dihydroxy vita-
mm D suppressed parathyroid hormone production.
As far as I can discern, the suppression of parathy-
roid hormone production is related to an increase in
serum calcium concentrations and is not a direct
effect of the vitamin per se. To postulate that a
reduction in 1 ,25—dihydroxy vitamin D early in a
long course of renal failure leads to an increase in
parathyroid hormone production requires evidence
of a reduced serum calcium concentration. As I have
said repeatedly, there is no such evidence in this
patient. There is additional evidence, however, that
the less-studied vitamin D metabolite, 24,25—dihy-
droxy vitamin D, may inhibit parathyroid hormone
production directly, i.e., independently of the serum
concentration of calcium ions [8]. If this is true,
reduced production of this metabolite may directly
increase parathyroid hormone level. For this in-
crease to be important, it is necessary to postulate
either a disproportionate reduction in 24,25—dihy-
droxy vitamin D in this patient or an inordinate
sensitivity to its absence. These are highly specula-
tive possibilities and seem unlikely to serve as strong
affirmations that we are dealing with secondary and
ultimately tertiary hyperparathyroidism in this
instance.
Because this patient had serum calcium and phos-
phorus concentrations out of line with virtually all
patients developing renal failure, no evidence of
phosphate retention or prolonged hypocalcemia, and
hypercalcemia antedating major renal insufficiency, I
believe that the parathyroid hormone excess was
primary and initially unrelated to her renal disease.
The pathologic findings of chief cell hyperplasia give
me pause in putting this formulation forward, but
they do not override the rest of the evidence.
Viewing this patient's problem from several stand-
points for the sake of completeness, let me suggest
that she may have had primary hyperparathyroidism
for a long time, and that primary hyperparathyroid-
ism produced all of the clinical findings. With a little
imagination, we could argue that because calcium
phosphate was being deposited in the loop of Henle
and collecting duct cells, as occurs with hypercal-
cemia, tubular injury occurred and led to the release
of an antigen that stimulated an immunologic re-
sponse. The immunologic response of antibody and
antigen produced glomerular damage and protein-
uria. Due to fluctuating degrees of hypercalcemia,
tubular injury was intermittent, and episodes of gb-
merular damage recurred. In time, the process be-
came more persistent and produced greater injury.
This sequence of tubular injury leading to glomerular
damage has been postulated in other predominantly
interstitial diseases, such as sickle cell disease, and
has also been postulated as the basis of the protein-
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uria seen in experimental models of renal failure. In a
recent study of the effects of phosphate restriction in
preventing renal injury, it has been demonstrated
that phosphate restriction leads to a reduction in
proteinuria [9]. The authors postulate that the phos-
phate administration may lead to deposition of cal-
cium phosphate, tubular injury, and antibodies to
tubular antigens producing proteinuria. I will grant
that this formulation is rather farfetched, but I offer it
as a counterweight to the 24,25—dihydroxy vitamin D
speculation.
From a more practical standpoint, the important
question in this patient is, What processes might
have been slowed or prevented by effective treat-
ment of her hypercalcemia when it first appeared?
There are numerous ways of treating hypercalcemia,
but there is no really effective substitute for parathy-
roidectomy when hypercalcemia is secondary to hy-
perparathyroidism in a patient with renal insuffi-
ciency. Therefore, the form of therapy that should
have been instituted in this patient is not really in
question. My concern is, Which aspects of her prob-
lem might have been prevented? Hypercalcemia
leads to functional and anatomical lesions of the
kidney [101. Functionally, hypercalcemia interferes
with antidiuretic hormone action, which leads to a
nephrogenic diabetes insipid-like picture. Hypercal-
cemia also produces interference with sodium reab-
sorption in the tubule, which leads to a saline di-
uresis and possibly a very significant hypovolemic
state. Higher concentrations of serum calci urn pro-
duce increased afferent arteriolar resistance in the
glomeruli and increased arteriolar resistance
throughout the body. The result at the renal level is a
reduction in GFR, and the result at the systemic level
is the potential for the development of hypertension.
Acute hypercalcernia may lead to stimulation of hy-
drogen ion secretion and a transient alkalemia, but
the chronic effects of hypercalcemia on acid-base
regulation are more likely related to the deposition of
calcium in the collecting duct, causing impairment of
hydrogen ion secretion and the development of aci-
demia. Of perhaps greater importance is the fact that
deposition of calcium phosphate in the tubular cells
and interstitium may initiate interstitial injury and
fibrosis, a process that may persist and progress even
after the hypercalcemia is corrected.
Thus, it is clear that the physiologic effects of
hypercalcemia are capable of accelerating and com-
plicating many of the key problems of renal insuffi-
ciency, particularly the difficulties in volume homeo-
stasis, hydrogen ion balance, and blood pressure
regulation. The failure to treat hypercalcemia in its
early phases increases the possibility of renal injury
in every patient: in the patient with underlying renal
disease, this may sharply accelerate the rate of func-
tional deterioration.
In this patient, all of the functional changes might
have occurred at the same time that anatomical in-
jury was initiated. Calcium phosphate was deposited
in the cells of the loop of Henle and the collecting
duct, which led to injury of those cells and the
deposition of calcium phosphate in the tubular and
interstitial areas. The establishment of these deposits
of calcium initiated a fibrosing process, which might
very easily have progressed even after correction of
hypercalcemia. Thus, the hypercalcemia was capa-
ble of producing an intrinsic anatomical renal injury
and a functional abnormality in the kidney, which
added to the difficulties of hydrogen ion secretion,
maintenance of volume homeostasis, and regulation
of blood pressure in chronic renal failure.
Questions and answers
DR. J. P. KASSIRER: Does the maintenance of a
normal serum calcium concentration without supple-
mentary vitamin D in a patient who has undergone
subtotal parathyroidectomy for the secondary hyper-
parathyroidism of uremia imply that the patient has
continued hyperparathyroidism?
DR. S. 0. THIER: Following subtotal parathyroid-
ectomy, if the remaining parathyroid tissue is ade-
quale to maintain a normal serum calcium concentra-
tion, then the desired effect of the maneuver has
been achieved. It seems to me the next question is,
Can parathyroid activity be suppressed or not? If it
can't be suppressed, I would be somewhat con-
cerned that hyperparathyroidism might still pose a
problem. I doubt that I would do anything further
however as long as the serum calcium concentration
remains within the normal range.
DR. J. P. KASSIRER: Of course, if the serum cal-
cium concentration is 9 mgIlOO ml and the phospho-
rus is 12 mg/100 ml, as it was in this patient, the risk
for further calcification is probably rather high.
DR. S. 0. THIER: It is not clear what would hap-
pen in this type of patient if the phosphate concentra-
tion decreased to say 6.0 mg/l00 ml; Would the
serum calcium concentration increase above normal
with incomplete suppression of the parathyroid
gland, or would it increase and completely suppress
what was left of the parathyroid gland? I think one
would have to see which response occurs before
deciding on the next step.
DR. J. J. COHEN: Dr. Thier, is your routine prac-
tice to restrict dietary phosphate or administer a
phosphate binder in the early stages of renal failure?
DR. 5. 0. THIER: That is still a personal decision
that each nephrologist has to make. Unfortunately, I
don't think we have any solid data presently on
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which to base that decision. The experimental evi-
dence from animal models indicating that the rate of
renal insufficiency may be retarded by phosphate
restriction is suggestive, but a controlled study in
humans is yet to be reported.
DR. J. J. COHEN: We are confronted daily with the
decision of whether or not to advise phosphate re-
striction in patients with mild renal insufficiency. Not
only the benefits but the risks remain unclear. Al-
though the risks of administering phosphate binders
over the short run seem to be pretty low, we really
don't know what the risks are of long-term treat-
ment. There may be other problems.
DR. S. 0. THIER: We have good data based on
careful balance studies in experimental animals
showing that serum phosphorus can be maintained at
a normal level by reducing phosphate intake in pro-
portion to the reduction in GFR. Unfortunately, we
can't measure whether the phosphate intake is being
reduced proportionately when we give a patient a set
dose of a phosphate binder. The question is whether
we are giving the right amount or over-shooting the
mark and taking the risk of developing a phosphate-
depletion syndrome over a period of time. Until we
really have some way of estimating the risk, I think it
will remain a difficult clinical situation. Parathyroid
hormone determinations are not quite accurate
enough for this purpose; nephrogenous cyclic AMP
might prove to be a more reasonable way to measure
parathyroid activity clinically. At present, I usually
wait until the serum creatinine is 3 or 4 mg/lOO ml,
and then I prescribe phosphate binders. Perhaps I
ought to use phosphate binders before that degree of
renal functional impairment is reached. Theoreti-
cally, by preventing the hyperphosphatemia from
ever occuring, one could prevent the parathyroid
hormone levels from ever increasing; that would be
very good preventive medicine. I am too nervous to
attempt that just yet.
Reprint requests to Dr. S. 0. Thier, Department of'Internal
Medicine, Yale University School of' Medicine, Yale New Haven
Hospital, 333 Cedar Street, New Haven, Connecticut 06511,
U.S.A.
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